Therapy Detail

Therapy Name BI 754111
Therapy Description

BI 754111 is a monoclonal antibody that targets LAG3 and inhibits binding of MHC II molecules to increase cytokine production by T-cells and prevent tumor growth (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4547).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
BI 754111 Immune Checkpoint Inhibitor 99 LAG3 Antibody 10 BI 754111 is a monoclonal antibody that targets LAG3 and inhibits binding of MHC II molecules to increase cytokine production by T-cells and prevent tumor growth (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4547).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT03697304 Phase II BI 754091 BI 754111 Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours. Recruiting
NCT03156114 Phase I BI 754091 BI 754111 This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. Recruiting